Literature DB >> 9396689

Clinical and epidemiologic features of Guillain-Barré syndrome.

R A Hughes1, J H Rees.   

Abstract

Guillain-Barré syndrome (GBS) is defined clinically as a peripheral neuropathy causing limb weakness that progresses for up to 4 weeks before reaching a plateau. The symptoms may be caused by inflammatory demyelination, axonal degeneration, or both. GBS occurs throughout the world, with a median incidence of 1.3 cases/100,000 population (range, 0.4-4.0). Males are more commonly affected than females, and there are peaks in young adults and the elderly. There is no clear seasonal association in Western countries, although this may be because the most frequent antecedent events, respiratory and enteric infections, have opposite seasonality. The most frequently identified cause of GBS is Campylobacter jejuni infection, which has been identified in up to 41% of patients and is associated with more severe disease and prolonged disability. Summer epidemics of GBS occur among children and young adults in Northern China and are particularly likely to be associated with C. jejuni infection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9396689     DOI: 10.1086/513793

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  94 in total

Review 1.  Mechanisms for the induction of autoimmunity by infectious agents.

Authors:  K W Wucherpfennig
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

2.  Pathogenesis and treatment of immune-mediated neuropathies.

Authors:  Helmar C Lehmann; Gerd Meyer Zu Horste; Bernd C Kieseier; Hans-Peter Hartung
Journal:  Ther Adv Neurol Disord       Date:  2009-07       Impact factor: 6.570

3.  Factors associated with long-term functional outcomes and psychological sequelae in Guillain-Barre syndrome.

Authors:  F Khan; J F Pallant; L Ng; A Bhasker
Journal:  J Neurol       Date:  2010-07-13       Impact factor: 4.849

4.  Alteration of cystatin C levels in cerebrospinal fluid of patients with Guillain-Barré Syndrome by a proteomical approach.

Authors:  Yinrong Yang; Shilian Liu; Zhaoyu Qin; Yazhou Cui; Yanjiang Qin; Shumei Bai
Journal:  Mol Biol Rep       Date:  2008-03-29       Impact factor: 2.316

5.  Toxoplasma gondii-associated Guillain-Barré syndrome in an immunocompetent patient.

Authors:  P Bossi; E Caumes; L Paris; M L Dardé; F Bricaire
Journal:  J Clin Microbiol       Date:  1998-12       Impact factor: 5.948

Review 6.  Immunotherapy of Guillain-Barré syndrome.

Authors:  Shuang Liu; Chaoling Dong; Eroboghene Ekamereno Ubogu
Journal:  Hum Vaccin Immunother       Date:  2018-07-12       Impact factor: 3.452

7.  Detection of Campylobacter DNA using magnetic nanoparticles coupled with PCR and a colorimetric end-point system.

Authors:  Wuttichote Jansaento; Kulachart Jangpatarapongsa; Duangporn Polpanich; Wijit Wonglumsom
Journal:  Food Sci Biotechnol       Date:  2016-02-29       Impact factor: 2.391

Review 8.  Immunomodulatory therapies in neurologic critical care.

Authors:  Logan M McDaneld; Jeremy D Fields; Dennis N Bourdette; Anish Bhardwaj
Journal:  Neurocrit Care       Date:  2009-09-23       Impact factor: 3.210

9.  Risk factors for sporadic Campylobacter jejuni infections in rural michigan: a prospective case-control study.

Authors:  Rachel Church Potter; John B Kaneene; William N Hall
Journal:  Am J Public Health       Date:  2003-12       Impact factor: 9.308

Review 10.  Guillain-Barré syndrome, transverse myelitis and infectious diseases.

Authors:  Yhojan Rodríguez; Manuel Rojas; Yovana Pacheco; Yeny Acosta-Ampudia; Carolina Ramírez-Santana; Diana M Monsalve; M Eric Gershwin; Juan-Manuel Anaya
Journal:  Cell Mol Immunol       Date:  2018-01-29       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.